Literature DB >> 16226111

Expression of the estrogen receptor beta in 37 surgically treated pulmonary sclerosing hemangiomas in comparison with non-small cell lung carcinomas.

Chen-Tu Wu1, Yih-Leong Chang, Yung-Chie Lee.   

Abstract

Sclerosing hemangioma (SH) of the lung is an uncommon tumor with a predilection for middle-aged women. This special phenomenon prompted us to examine SH for the expression of ERalpha (human estrogen receptor) and ERbeta (a second isoform of estrogen receptor). To investigate the staining pattern of these tumors, we also stained lung tissues from patients with non-small cell lung carcinomas and nonneoplastic type II pneumocytes for comparison. Thirty-seven pulmonary SHs and 301 non-small cell lung cancers specimens were explored. Expression of ERalpha and ERbeta was immunohistochemically measured. The overall frequency of overexpression for ERbeta was 91.9%. It was detected in both female (in 91.4% of 35 cases) and male (in 100.0% of 2 tumors from men) patients. There was ERbeta overexpression in all 9 tumors of solid pattern, 6 of 7 tumors of papillary pattern, all 4 tumors of sclerotic pattern, 12 of 13 tumors of hemorrhagic pattern, and 3 of 4 tumors of mixed pattern. The staining pattern of the neoplastic cells of the SH was similar to that of type II pneumocytes adjacent to the tumor rather than that of non-small cell lung cancers, in which the frequency of ERbeta overexpression was 45.8%. However, there was no ERalpha detectable in these neoplasms. Estrogen receptor beta overexpression is very frequent in pulmonary SHs, which is similar to that of alveolar cells but quite different from non-small cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226111     DOI: 10.1016/j.humpath.2005.08.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women.

Authors:  Jessica K Paulus; Wei Zhou; Peter Kraft; Bruce E Johnson; Xihong Lin; David C Christiani
Journal:  Lung Cancer       Date:  2010-07-23       Impact factor: 5.705

Review 2.  Targeting Nuclear Receptors in Lung Cancer-Novel Therapeutic Prospects.

Authors:  Shailendra Kumar Gangwar; Aviral Kumar; Kenneth Chun-Hong Yap; Sandra Jose; Dey Parama; Gautam Sethi; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-18

3.  Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer.

Authors:  Xiang-Qi Chen; Li-Xian Zheng; Zhi-Ying Li; Ting-Yan Lin
Journal:  J Int Med Res       Date:  2016-12-07       Impact factor: 1.671

4.  18 F-FDG PET/CT imaging: A supplementary understanding of pulmonary sclerosing pneumocytoma.

Authors:  Jie Xu; Youwen Dong; Guotao Yin; Wei Jiang; Zhen Yang; Wengui Xu; Lei Zhu
Journal:  Thorac Cancer       Date:  2019-05-27       Impact factor: 3.500

5.  [Analysis of Clinical Characteristics of 35 Cases 
of Pulmonary Sclerosing Pneumocytoma].

Authors:  Xiaojing Liu; Zhihao Huang; Jianyong Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-12-20

6.  Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer.

Authors:  Weiwei Yu; Jie Ding; Maio He; Yuan Chen; Ronghao Wang; Zhenwei Han; Emily Z Xing; Cuntai Zhang; Shuyuan Yeh
Journal:  Oncogene       Date:  2018-09-24       Impact factor: 8.756

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.